logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
Showing 1 - 2 of 2 Items
Showing 1 - 2 of 2 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high HIV burden rural South Africa: a retrospective cohort analysis

Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB,  et al.
2020-12-29 • Clinical Infectious Diseases
2020-12-29 • Clinical Infectious Diseases
Background
At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and two months of linezolid (LZD) for all patients initiating the shorter 9 to...
Journal Article
|
Research

Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high Human Immunodeficiency Virus (HIV) burden rural South Africa: a retrospective cohort analysis

Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB,  et al.
2021-11-02 • Clinical Infectious Diseases
2021-11-02 • Clinical Infectious Diseases
BACKGROUND
At the end of 2018, South Africa updated its all-oral regimen to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9-12 mon...